N@N

Market Maker Surveillance Report. GNVC, CSLT, CUR, IMUC, ETRM, NVDQ, Losing Stocks With Lowest Price Friction For Wednesday, J

^{Published on 2017-01-11 18:45:15 - WOPRAI}
 

January 11, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 5430 companies with "abnormal" market making, 3658 companies with positive Friction Factors and 2375 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. GenVec, Inc. (NASDAQ:GNVC), Castlight Health Inc. (NYSE:CSLT), Neuralstem Inc. (NASDAQ:CUR), ImmunoCellular Therapeutics Ltd (NYSE:IMUC), EnteroMedics Inc. (NASDAQ:ETRM), Novadaq Technologies Inc. (NASDAQ:NVDQ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  GNVC    $-2.540   -0.29%    596,967      32.19%    663,651      35.79%    -66,684      -263    
  CSLT    $-0.650   -0.15%    199,053      27.92%    297,911      41.79%    -98,858      -1,521  
  CUR     $-1.410   -0.23%    674,502      34.91%    723,618      37.45%    -49,116      -348    
  IMUC    $-1.420   -0.34%    264,324      33.85%    292,656      37.48%    -28,332      -200    
  ETRM    $-12.310  -0.44%    3,352,913    27.97%    3,683,988    30.73%    -331,075     -269    
  NVDQ    $-1.150   -0.15%    1,205,422    31.72%    1,567,341    41.24%    -361,919     -3,147  

For example, the chart above shows GNVC with a dollar loss Wednesday of $-2.54000 and a Friction Factor of -263 shares. That means that it only took 263 more shares of selling than buying to move GNVC lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

GenVec, Inc. (NASDAQ:GNVC) - GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform in the United States. It designs, tests, and manufactures adenoviral-based product candidates. The company s lead product candidate, CGF166 is in Phase I/II clinical trials for the treatment of hearing loss and balance disorders. It is also developing GV2311 vaccine for respiratory syncytial virus; and GV2207 vaccine for the treatment of herpes simplex virus. The company has a collaboration agreement with Novartis AG to develop CGF166. It also has collaboration agreement with TheraBiologics, Inc. to develop cancer therapeutics; National Institute of Allergy and Infectious Diseases to create and test various malaria vaccine candidates; and Merial Limited to develop and commercialize vaccine and anti-viral candidates for the prevention and containment of foot-and-mouth diseases in livestock and other animals. The company was founded in 1992 and is based in Gaithersburg, Maryland..

Castlight Health Inc. (NYSE:CSLT) - COMMUNITY SHARES LTD.

Neuralstem Inc. (NASDAQ:CUR) - Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds. The company s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical development products include NSI-189, which has completed Phase I clinical trial for the treatment of major depressive disorder, as well as is in Phase I clinical trial for the treatment of other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy; and NSI 566 that has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. The company was founded in 1996 and is headquartered in Germantown, Maryland..

ImmunoCellular Therapeutics Ltd (NYSE:IMUC) - ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing other therapeutic DC vaccines, such as ICT-140 for ovarian cancer; and ICT-121 to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California..

EnteroMedics Inc. (NASDAQ:ETRM) - EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. The company develops the Maestro Rechargeable System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It has collaboration with Mayo Clinic for the development and testing of products for the treatment of obesity. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota..

Novadaq Technologies Inc. (NASDAQ:NVDQ) - .

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net